Phaseline

Companies › CDR-Life

CDR-Life: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 1; Oncology; next expected readout Dec 2026.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
CDR404
T-cell engaging bispecific antibody targeting MAGE-A4
MAGEA4Phase 1Select Advanced Solid TumorsDec 2026

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06402201CDR404Phase 1Select Advanced Solid TumorsOncologyDec 2026

Targets

MAGEA4 (1)

Companies with the same targets

Zelluna Immunotherapy PDC*line Pharma SAS USWM CT

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.